To our knowledge, neither IGFBP-1 nor SERPINF2 gene expression has previously been investigated in individuals with various degrees of NAFLD, and the few existing studies concerning these candidate genes/gene products are further limited by missing comparison of expression levels and plasma protein concentrations. The gene discussed is SERPINF2; the disease is metabolic dysfunction-associated steatotic liver disease.